About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2024№12
Antibacterial therapy in pelvic inflammatory...

Antibacterial therapy in pelvic inflammatory diseases: current trends

DOI
https://dx.doi.org/10.18565/aig.2024.285

Dovletkhanova E.R., Abakarova P.R.

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia

The article presents a comprehensive analysis of the scientific literature on antimicrobial therapy for pelvic inflammatory diseases (PID). This is a literature review of the data obtained from the world sources in PubMed (the National Library of Medicine), Cochrane Library, Medline, and scientific citation databases (Scopus, Web of Science) for the period from 2005 to 2024.
Sexually transmitted infections are the primary cause of PID, but recent publications point to anaerobic microorganisms as a significant etiologic factor. PID represents a significant clinical and public health issue due to its potential to cause infertility. Broad-spectrum antibiotics are the principal drugs used in the treatment of PID. Antibacterial therapy regimens for PID follow certain principles and are aimed at eliminating the main pathogens, namely Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium. The polymicrobial nature of PID is also taken into account in the current recommendations for its treatment. One antibacterial drug that meets all the principles of the prescribed therapy and is included in almost all treatment regimens for PID is doxycycline. The novel form of the well-known and widely used antibiotic, Doxycycline EXPRESS, is the bioequivalent of the original drug, doxycycline monohydrate, in the form of dispersible tablets.
Conclusion: Currently, antibiotic resistance in the treatment of women with PID remains a complex medical problem. Doxycycline has an advantage in antimicrobial activity against intracellular pathogens including Chlamydia trachomatis and Mycoplasma genitalium. Doxycycline monohydrate demonstrates improved tolerability and eliminates the development of a number of side effects associated with tetracycline-type drugs. Due to the rapid release and even distribution of the active ingredient in the blood when taking the dispersible tablet (Doxycycline EXPRESS), higher concentrations are achieved in the area of the infectious lesion that help to overcome antibiotic resistance.

Authors’ contributions: Dovletkhanova E.R., Abakarova P.R. – developing the concept and design of the study, collecting and processing the material, selection of literature on the stated issue, writing the text, editing.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Dovletkhanova E.R., Abakarova P.R. Antibacterial therapy in pelvic inflammatory diseases: current trends.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (12): 176-184 (in Russian)
https://dx.doi.org/10.18565/aig.2024.285

Keywords

pelvic inflammatory diseases
PID
antibiotic therapy
doxycycline
doxycycline monohydrate
doxycycline EXPRESS
Full text (in Russian)

References

  1. Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б., ред. Гинекология. Национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2020. 1056 с. [Savelyeva G.M., Sukhikh G.T., Serov V.N., Radzinsky V.E., Manukhin I.B., ed. Gynecology. National Guide. 2nd ed. Moscow:GEOTAR-Media; 2020. 1056 p. (in Russian)].
  2. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021. Pelvic Inflammatory Disease (PID). Available at: https://www.cdc.gov/std/treatment-guidelines/pid.htm (accessed February 28, 2022).
  3. Ross J., Guaschino S., Cusini M., Jensen J. 2017 European guideline for the management of pelvic inflammatory disease. Int. J. STD AIDS. 2018; 29(2): 108-14. https://dx.doi.org/10.1177/0956462417744099.
  4. British Association for Sexual Health and HIV (BASHH). PID 2019. Available at: https://www.bashh.org/resources/6/pid_2019/
  5. Kreisel K., Torrone E., Bernstein K., Hong J., Gorwitz R. Prevalence of pelvic inflammatory disease in sexually experienced women of reproductive age – United States, 2013–2014. MMWR Morb. Mortal. Wkly Rep. 2017; 66(3): 80-3. https://dx.doi.org/10.15585/mmwr.mm6603a3.
  6. Yusuf H., Trent M. Pelvic inflammatory disease in adolescents. In: Reference Module in Biomedical Sciences. Elsevier; 2020. https://dx.doi.org/10.1016/B978-0-12-818872-9.00005-4.
  7. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Воспалительные болезни женских тазовых органов. 2021. [Ministry of Health of the Russian Federation. Clinical guidelines. Inflammatory diseases of the female pelvic organs. 2021.(in Russian)].
  8. BASHH. 2018. United Kingdom National Guideline for the management of pelvic inflammatory disease. Available at: https://www.bashh.org/_userfiles/pages/files/resources/pid2018.pdf
  9. Brun J.L., Castan B., de Barbeyrac B., Cazanave C., Charvériat A., Faure K., Mignot S. et al.; CNGOF; SPILF. Pelvic inflammatory diseases: Updated French guidelines. J. Gynecol. Obstet. Hum. Reprod. 2020; 49(5): 101714. https://dx.doi.org/10.1016/j.jogoh.2020.101714.
  10. Ross J.D. Pelvic inflammatory disease. Am. Fam. Phys. 2014; 90(10):725-6.
  11. Серов В.Н., Сухих Г.Т., Прилепская В.Н., Радзинский В.Е., ред. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. 3-е изд. М.: ГЭОТАР-Медиа; 2016. 1136 с. [Serov V.N., Sukhikh G.T., Prilepskaya V.N., Radzinsky V.E., ed. Guidelines for outpatient care in obstetrics and gynecology. 3rd ed. Moscow: GEOTAR-Media; 2016. 1136 p. (in Russian)].
  12. Прилепская В.Н., Сехин С.В. Воспалительные заболевания органов малого таза: диагностика и тактика ведения больных. Российский вестник акушера-гинеколога. 2015; 14(4): 101-6. [Prilepskaia V.N., Sekhin S.V. Small pelvic inflammatory diseases: Diagnosis and patient management tactics. Russian Bulletin of Obstetrician-Gynecologist. 2015; 15(4): 101-6. (in Russian)]. https://dx.doi.org/10.17116/rosakush2015154101-106.
  13. Ness R.B., Smith K.J., Chang C.C., Schisterman E.F., Bass D.C.; Gynecologic Infection Follow-Through, GIFT, Investigators. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sex. Transm. Dis. 2006; 33(3): 137-42. https://dx.doi.org/10.1097/01.olq.0000187205.67390.d1.
  14. Price M.J., Ades A.E., Welton N.J., Simms I., Macleod J., Horner P.J. Proportion of pelvic inflammatory disease cases caused by chlamydia trachomatis: consistent picture from different methods. J. Infect. Dis. 2016; 214(4): 617-24. https://dx.doi.org/10.1093/infdis/jiw178.
  15. Rowley J., Vander Hoorn S., Korenromp E., Low N., Unemo M., Abu-Raddad L.J. et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull. World Health Organ. 2019; 97(8): 548-562P. https://dx.doi.org/10.2471/BLT.18.228486.
  16. Sethi S., Singh G., Samanta P., Sharma M. Mycoplasma genitalium: an emerging sexually transmitted pathogen. Indian J. Med. Res. 2012; 136(6): 942-55.
  17. Hughes G., Saunders J. Mycoplasma genitalium: the next sexually transmitted superbug? BMJ. 2018; 363: k4376. https://dx.doi.org/10.1136/bmj.k4376.
  18. Tuddenham S., Hamill M.M., Ghanem K.G. Diagnosis and treatment of sexually transmitted infections: a review. JAMA. 2022; 327(2): 161-72.https://dx.doi.org/10.1001/jama.2021.23487.
  19. Bjartling C., Osser S., Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am. J. Obstet. Gynecol. 2012; 206(6): 476.e1-8. https://dx.doi.org/10.1016/j.ajog.2012.02.036.
  20. Chen P.C., Li P.C., Ding D.C. Pelvic inflammatory disease and causative pathogens in older women in a medical center in eastern Taiwan: a retrospective cross-sectional study. PLoS One. 2021; 16(9): e0257627. https://dx.doi.org/10.1371/journal.pone.0257627.
  21. Wang Y., Zhang Y., Zhang Q., Chen H., Feng Y. Characterization of pelvic and cervical microbiotas from patients with pelvic inflammatory disease. J. Med. Microbiol. 2018; 67(10):1519-26. https://dx.doi.org/10.1099/jmm.0.000821.
  22. Ness R.B., Soper D.E., Holley R.L., Peipert J., Randall H., Sweet R.L. et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am. J. Obstet. Gynecol. 2002; 186(5): 929-37. https://dx.doi.org/10.1067/mob.2002.121625.
  23. WHO. Sexually transmitted infections (STIs). 21 May 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
  24. Boujemaa S., Mlik B., Ben Allaya A., Mardassi H., Ben Abdelmoumen Mardassi B. Spread of multidrug resistance among Ureaplasma serovars, Tunisia. Antimicrob. Resist. Infect. Control. 2020; 9(1): 19. https://dx.doi.org/10.1186/s13756-020-0681-5.
  25. Cazanave C., Manhart L.E., Bébéar C. Mycoplasma genitalium, an emerging sexually transmitted pathogen. Med. Mal. Infect. 2012; 42(9): 381-92. https://dx.doi.org/10.1016/j.medmal.2012.05.006.
  26. Chernova O.A., Medvedeva E.S., Mouzykantov A.A., Baranova N.B., Chernov V.M. Mycoplasmas and their antibiotic resistance: the problems and prospects in controlling infections. Acta Naturae. 2016; 8(2): 24-34.
  27. Markley J.L., Fang L., Gasparrini A.J., Symister C.T., Kumar H., Tolia N.H. et al. Semisynthetic analogues of anhydrotetracycline as inhibitors of tetracycline destructase enzymes. ACS Infect. Dis. 2019; 5(4): 618-33. https://dx.doi.org/10.1021/acsinfecdis.8b00349.
  28. Chukwudi C.U. rRNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob. Agents Chemother. 2016; 60(8): 4433-41. https://dx.doi.org/10.1128/AAC.00594-16.
  29. Chukwudi C.U., Good L. Interaction of the tetracyclines with double-stranded RNAs of random base sequence: new perspectives on the target and mechanism of action. J. Antibiot. (Tokyo). 2016; 69(8): 622-30. https://dx.doi.org/10.1038/ja.2015.145.
  30. Short V.L., Totten P.A., Ness R.B., Astete S.G., Kelsey S.F., Haggerty C.L. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin. Infect. Dis. 2009; 48(1): 41-7. https://dx.doi.org/10.1086/594123.
  31. Páez-Canro C., Alzate J.P., González L.M., Rubio-Romero J.A., Lethaby A., Gaitán H.G. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst. Rev. 2019; 1(1): CD010871. https://dx.doi.org/10.1002/14651858.CD010871.pub2.
  32. Savaris R.F., Fuhrich D.G., Maissiat J., Duarte R.V., Ross J. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst. Rev. 2020; 8(8): CD010285. https://dx.doi.org/10.1002/14651858.CD010285.pub3.
  33. Higgins J.P.T., Lasserson T., Chandler J., Tovey D., Churchill R. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Cochrane:London; 2016.
  34. Wiesenfeld H.C., Meyn L.A., Darville T., Macio I.S., Hillier S.L. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic inflammatory disease. Clin. Infect. Dis. 2021; 72(7): 1181-9. https://dx.doi.org/10.1093/cid/ciaa101.
  35. St Cyr S., Barbee L., Workowski K.A., Bachmann L.H., Pham C., Schlanger K. et al. Update to CDC's Treatment Guidelines for gonococcal infection, 2020. MMWR Morb. Mortal. Wkly Rep. 2020; 69(50): 1911-6.https://dx.doi.org/10.15585/mmwr.mm6950a6.
  36. Tuddenham S., Hamill M.M., Ghanem K.G. Diagnosis and treatment of sexually transmitted infections: a review. JAMA. 2022; 327(2): 161-72.https://dx.doi.org/10.1001/jama.2021.23487.
  37. Kenyon C. Doxycycline post-exposure prophylaxis could theoretically select for resistance to various antimicrobials in 19 pathobionts: an in silico analysis. Int. J. Infect. Dis. 2024; 142: 106974. https://dx.doi.org/10.1016/j.ijid.2024.02.017.
  38. Stewart J., Oware K., Donnell D., Violette L.R., Odoyo J., Soge O.O. et al.; dPEP Kenya Study Team. Doxycycline prophylaxis to prevent sexually transmitted infections in women. N. Engl. J. Med. 2023; 389(25): 2331-40.https://dx.doi.org/10.1056/NEJMoa2304007.
  39. Baumann L., Cina M., Egli-Gany D., Goutaki M., Halbeisen F.S., Lohrer G.R. et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex. Transm. Infect. 2018; 94(4): 255-62. https://dx.doi.org/10.1136/sextrans-2017-053384.
  40. Haggerty C.L., Ness R.B. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. Expert Rev. Anti Infect. Ther. 2006; 4(2): 235-47.https://dx.doi.org/10.1586/14787210.4.2.235.
  41. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Хламидийная инфекция. 2023. [Ministry of Health of the Russian Federation. Clinical guidelines. Chlamydia infection. 2023.(in Russian)].
  42. Trent M. Pelvic inflammatory disease. Pediatr. Rev. 2013; 34(4): 163-72.https://dx.doi.org/10.1542/pir.34.4.163.
  43. WHO Guidelines for the Treatment of Chlamydia trachomatis. Geneva: World Health Organization; 2016.
  44. Dean G., Whetham J., Soni S., Pitt R., Alexander S. O031 Pelvic inflammatory disease (PID), mycoplasma genitalium and macrolide resistance in England. Sex. Transm. Infect. 2016; 92(Suppl. 1): A12.1-A12. https://dx.doi.org/10.1136/sextrans-2016-052718.30.
  45. Wood G.E., Bradshaw C.S., Manhart L.E. Update in epidemiology and management of Mycoplasma genitalium infections. Infect. Dis. Clin. North Am. 2023; 37(2): 311-33. https://dx.doi.org/10.1016/j.idc.2023.02.009.
  46. Trent M., Bass D., Ness R.B., Haggerty C. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex. Transm. Dis. 2011; 38(9): 879-81. https://dx.doi.org/10.1097/OLQ.0b013e31821f918c.
  47. Gossé M, Nordbø SA, Pukstad B. Evaluation of treatment with two weeks of doxycycline on macrolide-resistant strains of Mycoplasma genitalium: a retrospective observational study. BMC Infect Dis. 2021 Dec 7;21(1):1225. https://dx.doi.org/10.1186/s12879-021-06910-1.
  48. Инструкция по медицинскому применению лекарственного препарата «Доксициклин ЭКСПРЕСС». Доступно по: https://proantibiotiki.ru/docs/doxiciklin-express.pdf [Instructions for the medical use of the drug "Doxycycline EXPRESS". Available at: https://www.lsgeotar.ru/doxitsiklin-express-44984.html (in Russian)].
  49. Государственный реестр лекарственных средств. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3bc14514-4843-47f1-b01d-a931e88a0be7 [State Register of Medicines. Available at:https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3bc14514-4843-47f1-b01d-a931e88a0be7 (in Russian)].
  50. Перечень взаимозаменяемых лекарственных препаратов. Обновленный список. Государственный реестр лекарственных средств (ГРЛС) от 2 августа 2024 г. Доступно по: https://grls.rosminzdrav.ru/GRLS.aspx [List of interchangeable medicinal products. Updated list. State Register of Medicines (GRLS) dated August 2, 2024 Available at: https://grls.rosminzdrav.ru/GRLS.aspx (in Russian)].
  51. Зырянов С.К., Байбулатова Е.А. Использование новых лекарственных форм антибиотиков как путь повышения эффективности и безопасности антибактериальной терапии. Антибиотики и химиотерапия. 2019; 64(3-4): 81-91. [Zyryanov S.K., Baybulatova E.A. The use of new dosage forms of antibiotics as a way to improve the effectiveness and safety of antibiotic therapy. Antibiotics and Chemotherapy. 2019; 64(3-4): 81-91. (in Russian)]. https://dx.doi.org/10.24411/0235-2990-2019-10020.
  52. Белоусов Ю.Б., Данилов А.Н., Зырянов С.К., Рачина С.А. Доксициклинассоциированный лекарственный эзофагит: современные фармакологические возможности решения клинической проблемы. Consilium Medicum. 2012; 14(4): 57-63. [Belousov Yu.B., Danilov A.N., Zyryanov S.K., Rachina S.A. Doxycycline-associated drug esophagitis: modern pharmacological possibilities of solving a clinical problem. Consilium Medicum. 2012; 14(4): 57-63. (in Russian)].

Received 08.11.2024

Accepted 12.11.2024

About the Authors

Elmira R. Dovletkhanova, PhD, Senior Researcher, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 4, Oparin str., Moscow, Russia, 117997,
e_dovletkhanova@oparina4.ru, https://orcid.org/0000-0003-2835-6685
Patimat R. Abakarova, PhD, Senior Researcher, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 4, Oparin str., Moscow, Russia, 117997,
p_abakarova@oparina4.ru, https://orcid.org/0000-0002-8243-5272

Similar Articles

№12 / 2016
Rakhmatulina M.R., Shashkova A.A.
The clinical significance of detecting genital mycoplasmas and the current indicators of antibiotic susceptibility of Ureaplasma and M. hominis
№6 / 2017
Dikke G.B.
Polymicrobial associations in the etiology of inflammatory diseases of the female genital organs
№6 / 2022
Ievleva K.D., Danusevich I.N., Suturina L.V.
Features of interaction of Toll-like receptors with virus infection of the reproductive tract as a predictor of chronic endometritis
№2 / 2014
Kuznetsova I.V., Suleimanova N.S.
Use of immunomodulators in the therapy of cervicitis
№4 / 2018
Sgibnev A.V., Kremleva E.A., Shchetinina Yu.S., Cherkasova Yu.I.
Combined use of antibiotics and probiotics as a way to enhance the efficiency of treatment for genital infections
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.